Project
MK-3475-054
Ongoing - recruitment closed · 2016 until 2099
Fehr Martin, Hutter Franziska, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2016
End Date
2099
Financing
Industry
Labels
melanoma
Brief description/objective
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.